Erçelik, MelisTunca, BerrinAk Aksoy, SeçilTekin, ÇağlaTezcan, Gülçin2024-09-262024-09-262023-04-011304-530Xhttps://doi.org/10.4274/tjps.galenos.2022.57639https://turkjps.org/articles/doi/tjps.galenos.2022.57639https://hdl.handle.net/11452/45296Objectives: The purpose of this study was to investigate the effect of Olea europaea L. leaf extract (OLE) on senescence and senescence-associated secretory phenotype (SASP) caused by temozolomide (TMZ) in glioblastoma (GB).Materials and Methods: A senescence beta-galactosidase assay and a colony formation assay were used to determine the effects of OLE, TMZ, and OLE + TMZ on the cellular senescence and aggressiveness of GB cell lines T98G and U87MG. mRNA expression levels of p53, a senescence factor, interleukin (IL)-6, matrix metalloproteinases (MMP)-9, and nuclear factor kappa B1 (NF-kappa B1) as SASP factors and Bcl-2 and Bax as senolytic markers were assessed using quantitative reverse transcription-real-time polymerase chain reaction. Cells were double-stained with acridine orange and propidium iodide to observe the cell morphology.Results: TMZ increased the senescence rate of GB cells (p<0.001). Besides, OLE + TMZ reduced the proportion of senescent cells (p<0.001) and their capability to form colonies compared to TMZ-only-treated cells. Additionally, OLE + TMZ co-treatment elevated the mRNA expression levels of MMP-9, IL-6, NF-kappa B1, p53, and the Bax/Bcl-2 ratio compared to TMZ-only treatment. Especially in U87MG cells, involvement of OLE in TMZ treatments increased more than six times in the Bax/Bcl-2 ratio compared to TMZ-only, which induced the apoptosis-like morphological features (p<0.0001).Conclusion: Collectively, our findings presented the inhibitory effect of OLE on TMZ-mediated SASP-factor production in GB and, accordingly, its potential contribution to elongate the time of recurrence.eninfo:eu-repo/semantics/openAccessCell senescenceIn-vitroApoptosisExpressionDifferentiationMethylationImprovesP53GlioblastomaOlea europaea leaf extractTemozolomideSenescenceSaspPharmacology & pharmacyArticle000995975600001687720210.4274/tjps.galenos.2022.57639